0.00
+0.0001(+100.00%)
Currency In USD
Address
9119 Gaither Road
Gaithersburg, MD 20877
United States of America
Phone
301 825 9810
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
February 12, 2021
| Name | Title | Pay | Year Born |
| Dr. Robert Douglas Knight M.D. | Chief Medical Officer | 454,771 | 1951 |
| Mr. John Trainer M.B.A. | Consultant | 1.33M | 1974 |
| Mr. Chad Rubin | Senior Vice President of Corporate Affairs | 0 | N/A |
| Mr. Matthew Schiller | Head of Business Development | 0 | N/A |
| Ms. Karen Haslbeck | Head of Human Resources | 0 | N/A |
| Dr. Daniel P. Bednarik | Senior Vice President of Molecular Engineering & Protein Design | 0 | N/A |
| Dr. Jack A. Ragheb M.D., Ph.D. | Senior Vice President of Translational Science | 0 | N/A |
| Mr. Craig R. Jalbert CIRA | President, Treasurer, CS, Principal Executive Officer, Financial Off, & Principal Accounting Off | 0 | 1962 |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.